Discordance between traditional pathologic and energy metabolic changes in very early Alzheimer's disease. Pathophysiological implications
- PMID: 10672264
- DOI: 10.1111/j.1749-6632.1999.tb07852.x
Discordance between traditional pathologic and energy metabolic changes in very early Alzheimer's disease. Pathophysiological implications
Abstract
These results suggest that neither the loss of entorhinal efferents nor cholinergic deficit explains all the metabolic features seen in very early AD. Given recent immunohistological evidence of massive glutamatergic synaptic alteration in early AD cortex and insights into neuronal and glial mechanisms of glucose metabolism, very early metabolic changes in AD probably reflect a significant impairment of glycolytic activities in the cortico-cortical glutamatergic systems in a preclinical stage of the disease. However, the exact mechanisms of such impairment in these neurons are yet to be determined.
Similar articles
-
Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease.Brain. 1999 Aug;122 ( Pt 8):1519-31. doi: 10.1093/brain/122.8.1519. Brain. 1999. PMID: 10430835
-
Synchronous nonmonotonic changes in functional connectivity and white matter integrity in a rat model of sporadic Alzheimer's disease.Neuroimage. 2021 Jan 15;225:117498. doi: 10.1016/j.neuroimage.2020.117498. Epub 2020 Oct 24. Neuroimage. 2021. PMID: 33164858
-
Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators.J Nucl Med. 1993 Oct;34(10):1681-7. J Nucl Med. 1993. PMID: 8410281
-
Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):486-510. doi: 10.1007/s00259-005-1762-7. Eur J Nucl Med Mol Imaging. 2005. PMID: 15747152 Review.
-
Biomarkers, ketone bodies, and the prevention of Alzheimer's disease.Metabolism. 2015 Mar;64(3 Suppl 1):S51-7. doi: 10.1016/j.metabol.2014.10.033. Epub 2014 Oct 30. Metabolism. 2015. PMID: 25468143 Review.
Cited by
-
Mechanisms underlying fatigue: a voxel-based morphometric study of chronic fatigue syndrome.BMC Neurol. 2004 Oct 4;4(1):14. doi: 10.1186/1471-2377-4-14. BMC Neurol. 2004. PMID: 15461817 Free PMC article.
-
Functional neuroimaging in Alzheimer's disease.Radiat Med. 2006 May;24(4):302-8. doi: 10.1007/s11604-006-2408-9. Radiat Med. 2006. PMID: 16958406 Review. No abstract available.
-
Phosphoinositides: Two-Path Signaling in Neuronal Response to Oligomeric Amyloid β Peptide.Mol Neurobiol. 2017 Jul;54(5):3236-3252. doi: 10.1007/s12035-016-9885-3. Epub 2016 Apr 14. Mol Neurobiol. 2017. PMID: 27080543
-
Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process.Brain. 2014 Aug;137(Pt 8):2356-67. doi: 10.1093/brain/awu159. Epub 2014 Jun 20. Brain. 2014. PMID: 24951642 Free PMC article.
-
Cerebrospinal Fluid-In Gradient of Cortical and Deep Gray Matter Damage in Multiple Sclerosis.Neurol Neuroimmunol Neuroinflamm. 2024 Jul;11(4):e200271. doi: 10.1212/NXI.0000000000200271. Epub 2024 Jun 19. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 38896808 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical